Charles River Laboratories International (NYSE:CRL) reported its Q4 and full-year 2025 earnings, with Q4 EPS missing expectations at -$5.62 against an anticipated $2.33. CEO James C. Foster announced his retirement in May, with Birgit H. Gershick appointed as the new CEO. The company provided 2026 guidance, expecting organic revenue to range from down 1% to flat, driven by improved DSA demand, strategic acquisitions, and cost-saving initiatives, despite some headwinds in RMS and Manufacturing.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International (NYSE:CRL) reported its Q4 and full-year 2025 earnings, with Q4 EPS missing expectations at -$5.62 against an anticipated $2.33. CEO James C. Foster announced his retirement in May, with Birgit H. Gershick appointed as the new CEO. The company provided 2026 guidance, expecting organic revenue to range from down 1% to flat, driven by improved DSA demand, strategic acquisitions, and cost-saving initiatives, despite some headwinds in RMS and Manufacturing.